Molnupiravir as an Early Treatment for COVID-19: A Real Life Study.
Michela PontolilloClaudio UcciferriPaola BorrelliMarta Di NicolaJacopo VecchietFalasca KatiaPublished in: Pathogens (Basel, Switzerland) (2022)
Participants treated with molnupiravir, albeit in risk categories, demonstrated early clinical improvement, no need for hospitalization, and a low rate of adverse events.